On 6 April 2006, orphan designation (EU/3/06/365) was granted by the European Commission to Wyeth Europa Limited, United Kingdom, for temsirolimus for the treatment of renal cell carcinoma.
The sponsorship was transferred to Pfizer Limited, United Kingdom, in September 2011.
Temsirolimus in treatment of renal cell carcinoma has been authorised in the EU as Torisel 19 November 2007.
|Disease / condition||
Treatment of renal-cell carcinoma
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.